Is chemotherapy‐induced neutropenia a prognostic factor in patients with ovarian cancer?
Authors:
- Jeong‐Yeol ParkJPJeong‐Yeol Park
- Yong‐Man KimYKYong‐Man Kim
- 1 May 2010
- journal article
- research article
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 89 (5) , 623-628
Abstract
Objective. This study sought to determine if relative neutropenia (RN) following six cycles of paclitaxel/carboplatin could serve as a prognostic factor in patients with ovarian cancer. Design. A single institution, retrospective study. Setting. Tertiary academic referral center, Seoul, Korea Population. A total of 179 patients who underwent primary cytoreductive surgery, followed by six cycles of paclitaxel/carboplatin chemotherapy to treat epithelial ovarian cancer. Methods. Relative neutropenia was defined by an absolute neutrophil count < 1000 neutrophils/mm3 at chemotherapy cycle nadir. To eliminate the effects of dose reduction (DR) and schedule delay (SD) on the outcome of analysis, 49 patients who had this were excluded, and a subset analysis of 130 patients who received standard doses and schedules of chemotherapy was performed. Main outcome measures. Progression free and overall survival. Results. The median progression free survival (PFSs) of neutropenic and non‐neutropenic patients was 34 and 22 months, respectively; the median overall survival (OS) times were 67 and 56 months, respectively, with no significant differences in PFS and OS (p = 0.26, 0.59). Multivariate analysis revealed that stage, clear cell histology, and ≥1 cm residual tumor mass were independent prognostic predictors, while RN was not. In the subset analysis confined to the patients without DR and SD, the results were not changed. Conclusion. Chemotherapy‐induced neutropenia was not a significant prognostic indicator in ovarian cancer patients treated with paclitaxel/carboplatin as first‐line chemotherapy.Keywords
This publication has 15 references indexed in Scilit:
- Neutropenia during adjuvant chemotherapy of breast cancer is not a predictor of outcomeActa Oncologica, 2009
- Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patientsGynecologic Oncology, 2008
- The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancerLung Cancer, 2006
- Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trialsThe Lancet Oncology, 2005
- Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian CarcinomaJNCI: Journal of the National Cancer Institute, 2004
- Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancerBritish Journal of Cancer, 2003
- Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinomaCancer, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI: Journal of the National Cancer Institute, 2000
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Prednimustine (sterecyt) versus cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancerEuropean Journal of Cancer, 1993